Last checked at 30 Mar 2011 07:00
For Immediate Release | 30 March 2011 |
ImmuPharma PLC
Notification of Preliminary Results
Date : 5 April 2011
ImmuPharma PLC (AIM:IMM), the specialist discovery and development pharmaceutical company, is scheduled to announce its Preliminary Results for the year ended 31 December 2010 on 5 April 2011.
An analyst meeting will be held at 10.00am on the day of the results. A webcast will run simultaneously to the meeting and will be available via the following link:
http://mediaserve.buchanan.uk.com/2011/immupharma050411/registration.asp
- Ends -
For further information, please contact:
ImmuPharma PLC:
Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 76 50
Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080
Richard Warr, Chairman +44 20 7152 4080
Buchanan Communications
Lisa Baderoon
Mark Court +44 20 7466 5000
Panmure, Gordon & Co., NOMAD & Broker
Andrew Burnett
Rakesh Sharma +44 20 7459 3600
Espirito Santo Investment Bank
James Bromhead
Richard Crawley +44 20 7456 9191
Notes to Editors:
About ImmuPharma
ImmuPharma PLC is a drug discovery and development company headquartered in London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by:
·; blockbuster potential in niche markets
·; low promotional costs in few specialised physicians and centres and
·; lower risk of drug development and lower development costs
ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections.
All three have significant sales potential as well as low marketing costs and a relatively low risk of development failure. One or more have the potential to be fast-tracked by the US Food and Drug Administration according to "Guidance for Industry: Fast Track Drug Development Programs - Designation, Development and Application Review" issued July 2004 and could therefore obtain their market authorization by 2010.
Key to the potential success of ImmuPharma is its unique collaborative agreement with Centre National de la Recherche Scientifique, France's scientific research institution. This agreement grants ImmuPharma worldwide exclusive rights to exploit certain key discoveries.
In addition to its three leading drug candidates, ImmuPharma has a drug development pipeline using its rights to a virtual chemical library of hundreds of thousands of molecules as well as an innovative technology for converting peptides to drug candidates.
ImmuPharma has the option to commercialise its assets itself or to license them to other pharmaceutical companies at an earlier stage.